Cerdulatinib (PRT062070, PRT2070)
97%
- Product Code: 100007
CAS:
1369761-01-2
| Molecular Weight: | 482 g./mol | Molecular Formula: | C₂₀H₂₈ClN₇O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Cerdulatinib is primarily used in the field of oncology as a targeted therapy for certain types of cancers. It functions as a dual inhibitor of SYK and JAK kinases, which are involved in signaling pathways that promote cancer cell growth and survival. This makes it particularly effective in treating hematologic malignancies such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and other B-cell malignancies. By blocking these kinases, cerdulatinib helps to inhibit the proliferation of cancer cells and induce apoptosis. It is also being investigated for its potential in overcoming resistance to other therapies, offering a promising option for patients with relapsed or refractory disease. Additionally, its oral bioavailability allows for convenient administration, enhancing patient compliance and quality of life during treatment.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Gray To Light Brown To Brown Solid |
| Purity (%) | 96.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | €85.00 |
+
-
|
Cerdulatinib (PRT062070, PRT2070)
Cerdulatinib is primarily used in the field of oncology as a targeted therapy for certain types of cancers. It functions as a dual inhibitor of SYK and JAK kinases, which are involved in signaling pathways that promote cancer cell growth and survival. This makes it particularly effective in treating hematologic malignancies such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and other B-cell malignancies. By blocking these kinases, cerdulatinib helps to inhibit the proliferation of cancer cells and induce apoptosis. It is also being investigated for its potential in overcoming resistance to other therapies, offering a promising option for patients with relapsed or refractory disease. Additionally, its oral bioavailability allows for convenient administration, enhancing patient compliance and quality of life during treatment.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :